This grant, part of the HEAL Initiative, is for the purpose of fostering the pre-clinical development of innovative pharmacotherapeutic candidates. The objective is to discover treatments that can specifically reverse opioid-induced respiratory depression (OIRD) – a critical aspect of overdose – without the negative side effects of either negating the pain-relieving effects of opioids or precipitating severe opioid withdrawal. This funding opportunity aims to advance promising compounds through initial stages of research, ensuring new life-saving interventions for opioid overdose can be explored while preserving necessary pain management functions. It focuses on target validation and early therapeutic development before clinical trials.
Opportunity ID: 335959
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-22-013 |
| Funding Opportunity Title: | HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.233 — National Center on Sleep Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 30, 2021 |
| Last Updated Date: | Sep 30, 2021 |
| Original Closing Date for Applications: | Dec 03, 2021 |
| Current Closing Date for Applications: | Dec 03, 2021 |
| Archive Date: | Jan 08, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public and State controlled institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Small businesses County governments Native American tribal governments (Federally recognized) City or township governments Special district governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) aims to stimulate the pre-clinical development of novel, pharmacotherapeutic candidates to selectively counteract opioid induced respiratory depression (OIRD), without blocking opioid analgesic benefits or inducing acute opioid withdrawal. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-013.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270476 | Nov 18, 2021 | Dec 03, 2021 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269159 | Nov 03, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
335959 RR_SF424_5_0-5.0.pdf
335959 PHS398_CoverPageSupplement_5_0-5.0.pdf
335959 RR_OtherProjectInfo_1_4-1.4.pdf
335959 PerformanceSite_4_0-4.0.pdf
335959 RR_KeyPersonExpanded_4_0-4.0.pdf
335959 RR_Budget_3_0-3.0.pdf
335959 PHS398_ResearchPlan_4_0-4.0.pdf
335959 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335959 RR_SubawardBudget30_3_0-3.0.pdf
335959 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335959 RR_SF424_2_0-2.0.pdf
335959 PHS398_CoverPageSupplement_5_0-5.0.pdf
335959 RR_OtherProjectInfo_1_4-1.4.pdf
335959 PerformanceSite_2_0-2.0.pdf
335959 RR_KeyPersonExpanded_2_0-2.0.pdf
335959 RR_Budget_1_4-1.4.pdf
335959 PHS398_ResearchPlan_4_0-4.0.pdf
335959 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335959 RR_SubawardBudget30_1_4-1.4.pdf
335959 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
